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OBJECTIVE — Many studies have documented associations between inﬂammation and type
2 diabetes incidence. We assessed potential variability in this association in the major U.S.
racial/ethnic groups.
RESEARCHDESIGNANDMETHODS — Incidenttype2diabeteswasassessedamong
men and women aged 45–84 years without prior clinical cardiovascular disease or diabetes in
the prospective Multi-Ethnic Study of Atherosclerosis. Interleukin (IL)-6, ﬁbrinogen, and C-re-
active protein (CRP) were measured at baseline (2000–2002); fasting glucose and diabetes
medication use was assessed at baseline and three subsequent in-person exams through 2007.
Type2diabeteswasdeﬁnedasuseofdiabetesdrugsorglucose126mg/dl.Covariatesincluded
baseline demographics, clinic, smoking, alcohol, exercise, hypertension medication, systolic
blood pressure, insulin resistance, and BMI. Cox proportional hazards regression was used to
calculate hazard ratios (HRs) by quartiles of CRP, IL-6, and ﬁbrinogen.
RESULTS — Among 5,571 participants (mean age 61.6 years, 53% female, 42.1% white,
11.5% Chinese, 25.7% black, and 20.7% Hispanic), 410 developed incident diabetes during a
median follow-up time of 4.7 years (incidence 16.8 per 1,000 person-years). CRP, IL-6, and
ﬁbrinogen levels were associated with incident diabetes in the entire sample. After adjustment,
theassociationswereattenuated;however,quartile4(versusquartile1)ofIL-6(HR1.5[95%CI
1.1–2.2]) and CRP (1.7 [1.3–2.4]) remained associated with incident diabetes. In stratiﬁed
analyses, similar associations were observed among white, black, and Hispanic participants.
CONCLUSIONS — Higher levels of inﬂammation predict short-term incidence of type 2
diabetes in a multiethnic American sample.
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A
number of prospective studies
(1–8) have demonstrated an asso-
ciation between high levels of in-
ﬂammation and the development of type
2 diabetes. In this report, we assess three
inﬂammatorymarkers:C-reactiveprotein
(CRP), interleukin (IL)-6, and ﬁbrinogen.
CRP is an acute-phase reactant mainly
producedintheliver.Recentstudieshave
shown that CRP can also be produced by
fat cells (9), which raises the possibility
that CRP may simply be a marker of obe-
sity in people who go on to develop dia-
betes. Fibrinogen is involved in clotting
butisalsoanacute-phasereactantandhas
been previously linked to incident diabe-
tes (8). IL-6 is made by leukocytes and
other tissues that play a role in glucose
homeostasis, including pancreatic islet
cells, hepatocytes, adipocytes, and skele-
tal muscle cells, and is associated with in-
cident diabetes (10). The graded positive
association between most inﬂammatory
markers and diabetes incidence remains
signiﬁcant following adjustment for es-
tablisheddiabetesriskfactors.However,a
study(11)inthePimapopulationshowed
no association between inﬂammatory
markers and the risk of diabetes after ad-
justing for established risk factors for di-
abetes. Although a sizable number of
studies have documented the inﬂamma-
tory marker–diabetes association, studies
on ethnic/racial variations in this associa-
tion are limited, despite the well-
documented increased prevalence of
diabetes in nonwhite populations in the
U.S. (12). The aims of this analysis are 1)
to explore the ability of CRP, IL-6, and
ﬁbrinogen to predict the incidence of
diabetes in a prospective, multiethnic
cohort and 2) to determine the extent to
which observed associations are similar
across racial/ethnic groups. We also con-
sider whether observed associations are
independent of the major known risk fac-
tors for diabetes (obesity, family history,
insulin resistance, hypertension, age, and
physical inactivity) (13).
RESEARCH DESIGN AND
METHODS— The Multi-Ethnic Study
of Atherosclerosis (MESA) is a popula-
tion-based sample of 6,814 men and
women from four ethnic groups (38%
white, 28% African American, 22% His-
panic, and 12% Chinese) aged 45–84
years without clinical cardiovascular dis-
ease (CVD) prior to recruitment. Details
regarding MESA’s design and objectives
have been published (14). Brieﬂy, sub-
jects who reported a medical history of
heart attack, angina, coronary revascular-
ization, pacemaker or deﬁbrillator im-
plantation, valve replacement, heart
failure, or cerebrovascular disease were
excluded. During the baseline exam
(2000–2002), standardized question-
naires and calibrated devices were uti-
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usage, medical conditions, current pre-
scription medication usage, weight, waist
circumference, and height. BMI was cal-
culated as weight (kilograms)/height
(meters)
2. Resting seated blood pres-
sure was measured three times using a
Dinamap automated oscillometric sphyg-
momanometer (model Pro 100; Critikon,
Tampa, FL); the last two measurements
were averaged for analysis. Hypertension
wasdeﬁnedbasedonuseofanantihyper-
tensive medication or systolic blood pres-
sure 140 mmHg or diastolic blood
pressure 90 mmHg. Education was cat-
egorized as less than high school, com-
pleted high school, some college/
technical school certiﬁcate or associate
degree, bachelor’s degree, and graduate
or professional school. We utilized the
MESA Typical Week Physical Activity
Survey intentional exercise variable, de-
ﬁned as the sum of walking for exercise,
sports/dancing, and conditioning meta-
bolic equivalent (MET) hours per week
(14). Alcohol use was queried and coded
as current/former/never. Participants
were asked about current or former ciga-
rette smoking, age at which smoking
started and ended, and number of daily
cigarettes typically consumed. Pack-years
was calculated, deﬁned as number years
smoking times packs per day (cigarettes
per day divided by 20). Family history of
diabetes was assessed at exam 2 and was
unavailable for those who missed that
exam.
Laboratory assessment
Fasting blood samples were drawn and
processed using a standardized protocol
and sent for measurement of glucose and
inﬂammatory markers to central labora-
tories (15). Serum glucose was measured
by the glucose oxidase method on the
Vitrosanalyzer(Johnson&JohnsonClin-
ical Diagnostics). Insulin was determined
byaradioimmunoassaymethodusingthe
Linco Human Insulin-Speciﬁc RIA Kit
(LincoResearch).Thehomeostasismodel
assessment of insulin resistance (HOMA-
IR)wascalculatedasinsulinmU/l(glu-
cose mg/dl  0.055)/22.5 (16). CRP and
ﬁbrinogen were measured using the BNII
nephelometer (N High-Sensitivity CRP
and N Antiserum to Human Fibrinogen;
Dade Behring). Intra-assay coefﬁcients of
variation (CVs) for CRP range from 2.3 to
4.4% and interassay CVs range from 2.1
to 5.7%. The intra-assay and interassay
CVs for ﬁbrinogen were 2.7 and 2.6%,
respectively. IL-6 was measured by ultra-
sensitive enzyme-linked immunosorbent
assay (Quantikine HS Human IL-6 Im-
munoassay; R&D Systems). The labora-
tory CV for the IL-6 assay was 6.3%.
Diabetes deﬁnition
Participants with diabetes at baseline, de-
ﬁned as using hypoglycemic drugs or if
thefastingglucosewas7.0mmol/l(126
mg/dl), were excluded from these analy-
ses. Subjects were considered to have im-
paired fasting glucose if they did not have
diabetes by the preceding criteria and
their fasting glucose was 5.6 and 7.0
mmol/l (100 and 126 mg/dl). Sub-
jects newly utilizing hypoglycemic medi-
cation or having fasting glucose 7
mmol/l at exams 2, 3, or 4 were consid-
ered to have incident type 2 diabetes.
Statistical analysis
Descriptive statistics were utilized to
compare characteristics of participants
who developed diabetes compared with
thosewhodidnot.Weprimarilyanalyzed
thesedatabydividingthepopulationinto
quartiles of each inﬂammatory variable.
We also noted that the distributions of
IL-6 and CRP were skewed and differed
by race (generally lower levels in Chinese
and higher in black participants). Thus,
we also assessed the relationship between
log-transformed IL-6 and CRP and inci-
dent diabetes separately in each racial/
ethnic group.
Unadjusted incidence rates were cal-
culated using person-time analysis. Par-
ticipants were censored at the last
follow-up exam that they attended (ex-
ams 2, 3, or 4). Cox proportional hazards
modeling was utilized to estimate hazard
ratios (HRs) associated across quartiles.
Model 1 included the inﬂammation
marker of interest, age, sex, race/ethnicity
site, exercise, education, systolic blood
pressure, antihypertensive medication
use, alcohol consumption, and smoking.
Model 2 included model 1 variables plus
HOMA-IR. Model 3 included model 2
variablesplusBMI.Allcovariateswerede-
ﬁned as their value at the baseline visit.
Potential interactions between each in-
ﬂammatory variable and race/ethnicity or
sex were assessed using a multivariable
interaction term. We performed addi-
tional analyses, ﬁrst replacing BMI with
waist circumference, and second adding
family history of diabetes to model 3,
which did not appreciably change our re-
sults; therefore, we do not present them.
Finally, we constructed a composite in-
ﬂammation score by standardizing the
distributions of IL-6 and CRP and averag-
ing the two. The sample was then divided
into quartiles according to the composite
score.Incidencerateswerecalculatedand
hazard ratios modeled as detailed above.
All analyses were performed using Stata
8.2 (Statacorp, College Station, TX).
RESULTS— After excluding 857
(12.5%) participants with diabetes at
baseline, 349 (5.1%) without a follow-up
visit, 25 (0.4%) missing exam 1 diabetes
status, and 12 (0.2%) missing all inﬂam-
matory markers at baseline, our ﬁnal
study sample was 5,571 individuals. Of
these, 410 were classiﬁed as having inci-
dent diabetes during a median follow-up
time of 4.7 years (incidence rate 16.5 per
1,000 person-years). Participant charac-
teristics, stratiﬁed by race/ethnicity, are
presented in Table 1. Overall, diabetes
risk factors differed signiﬁcantly between
racial/ethnic groups. Nonwhite partici-
pants had a greater prevalence of im-
paired fasting glucose at baseline and
higher incident diabetes rates than white
subjects. Chinese participants had, on av-
erage, a lower BMI and waist circumfer-
ence and less frequently reported a family
history of diabetes. Levels of all three in-
ﬂammation markers differed signiﬁcantly
by race/ethnicity (P  0.001). Mean IL-6,
CRP, and ﬁbrinogen were lower among
Chinese and tended to be higher among
Hispanic and black subjects when com-
pared with white subjects.
There was a modest level of correla-
tionbetweenpairsofinﬂammatorymark-
ers and between each marker and BMI
(online appendix Table [available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1679/DC1]). There was little to no
correlation between CRP/IL-6/ﬁbrinogen
and age, blood pressure, glucose, exer-
cise, and pack-years smoking. For each
marker, rates of incident diabetes were
higher for participants in higher quartiles
compared with the lowest quartile (Table
2). Diabetes incidence was threefold
higher among participants whose base-
line levels of CRP or IL-6 were in the
fourth versus the ﬁrst quartile. The rela-
tionship between ﬁbrinogen and inci-
dence appeared different, with only the
fourth quartile being signiﬁcantly ele-
vated compared with the lower three
quartiles. The univariate and adjusted as-
sociations between inﬂammation and di-
abetesareshowninTable2.Ingeneral,all
the observed associations remained sig-
niﬁcant after adjusting for demographic
factors, health behaviors, and blood pres-
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fourth quartile was signiﬁcantly associ-
ated with diabetes, and after adjusting for
HOMA there was no longer a linear trend;
with subsequent addition of BMI to the
model, there was no evidence for any asso-
ciation between level of ﬁbrinogen and dia-
betes. In contrast, while addition of HOMA
and BMI both attenuated the HRs, there re-
Table 1 —Characteristics of participants, by race/ethnicity, in MESA 2000–2007
White Chinese African American Hispanic
n 2,348 644 1,427 1,152
Age (years) 62.3  10.2 61.3  10.2 61.5  10.2 60.5  10.3
Female* 52.4% 51.7% 55.6% 52.6%
Current smoking 11.1% 5.4% 18.1% 13.7%
Pack-years (tobacco) 14.6  27.3 4.3  12.7 11.4  18.9 7.4  16.0
Former alcohol use 17.1% 15.5% 31.0% 24.3%
Current alcohol use 73.6% 32.2% 52.3% 51.1%
Education (more than a bachelor’s degree) 51.4 40.9 36.3 11.0
Exercise (MET hours/week) 28.4  37.3 19.7  26.5 29.9  48.4 22.8  35.5
Weight (lb) 173.7  36.4 138.3  24.3 186.6  37.4 168.7  32.1
BMI (kg/m
2) 27.5  4.9 23.9  3.3 29.8  5.8 29.1  4.8
Waist (cm) 97.2  14.1 86.6  10.1 99.8  14.2 99.5  12.7
Hypertension medication 30.7% 24.5% 44.6% 28.0%
Hypertension 36.6% 34.2% 54.7% 37.3%
Systolic blood pressure (mmHg) 122.6  19.9 122.8  21.1 130.6  21.2 125.2  21.3
Diastolic blood pressure (mmHg) 70.2  9.9 71.9  10.3 74.6  10.1 71.7  10.1
Glucose (mg/dl) 87.8  10.0 91.5  10.1 90.2  10.7 91.0  10.8
Impaired fasting glucose 10.4% 17.2% 15.9% 17.3%
HOMA-IR 1.3  1.0 1.4  1.0 1.5  1.1 1.7  1.3
Family history† 29.1% 25.6% 42.3% 41.0%
CRP (mg/l) 3.3  5.0 1.9  5.2 4.5  6.9 3.7  4.7
CRP 3.0 mg/l 32.6% 12.3% 43.2% 40.9%
IL-6 (pg/ml) 1.4  1.2 1.1  1.0 1.6  1.2 1.6  1.1
Fibrinogen (mg/dl) 332.4  68.7 327.6  60.2 357.3  77.4 354.0  70.5
Incident diabetes‡ 11.1/1,000 16.2/1,000 21.6/1,000 21.9/1,000
Data are means  SD, unless otherwise indicated. All differences across race/ethnicity are signiﬁcant at P  0.001 except *P  0.2. †Family history data available
for 5,404 subjects. ‡Rate per 1,000 person-years.
Table 2—HRs for incident diabetes associated with inﬂammatory markers in MESA 2002–2007
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend
n  5,554
CRP (mg/l) 0.15–0.80 0.81–1.80 1.81–4.08 4.09–97.4
Rate 9.0 13.4 16.7 27.4 0.001
Univariate 1 (referent) 1.5 (1.1–2.1) 1.9 (1.3–2.6) 3.1 (2.3–4.1) 0.001
Model 1 1 (referent) 1.5 (1.3–2.0) 1.8 (1.3–2.4) 2.8 (2.1–3.9) 0.001
Model 2 1 (referent) 1.3 (0.9–1.8) 1.5 (1.0–2.0) 2.1 (1.5–2.9) 0.001
Model 3 1 (referent) 1.2 (0.9–1.7) 1.3 (0.9–1.8) 1.7 (1.3–2.4) 0.01
n  5,445
IL-6 (pg/ml) 0.12–0.73 0.74–1.14 1.15–1.792 1.793–12.9
Rate 8.2 14.9 15.7 28.2 0.001
Univariate 1 (referent) 1.8 (1.3–3.5) 1.9 (1.4–2.7) 3.4 (2.5–4.6) 0.001
Model 1 1 (referent) 1.7 (1.2–2.4) 1.7 (1.2–2.4) 3.0 (2.2–4.2) 0.001
Model 2 1 (referent) 1.5 (1.1–2.1) 1.3 (0.9–1.8) 2.0 (1.4–2.8) 0.001
Model 3 1 (referent) 1.4 (1.0–2.0) 1.1 (0.8–1.6) 1.5 (1.1–2.2) 0.02
n  5,557
Fibrinogen (mg/l) 144–293 294–334 335–384 385–701
Rate 13.9 13.3 16.4 22.5 0.001
Univariate 1 (referent) 1.0 (0.7–1.3) 1.2 (0.9–1.6) 1.6 (1.2–2.1) 0.001
Model 1 1 (referent) 1.0 (0.7–1.3) 1.1 (0.8–1.5) 1.5 (1.1–2.0) 0.01
Model 2 1 (referent) 0.9 (0.7–1.2) 1.1 (0.8–1.4) 1.2 (0.9–1.6) NS
Model 3 1 (referent) 0.8 (0.6–1.1) 1.0 (0.7–1.3) 1.0 (0.8–1.3) NS
DataareHRs(95%CI).Rateisdeﬁnedastherateofincidentdiabetesper1,000person-years.Model1isadjustedforage,sex,race,education,site,alcohol,smoking,
exercise, systolic blood pressure, and antihypertensive medication use. Model 2  model 1 plus HOMA-IR. Model 3  model 2 plus BMI. P value for trend across
quartiles is noted. NS, not signiﬁcant.
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both CRP and IL-6 and diabetes incidence.
There was no statistical evidence of a
signiﬁcantinteractionbetweeninﬂamma-
tion level and race/ethnicity (or sex).
Nonetheless, given our primary study
aim, we performed stratiﬁed analyses for
CRP and IL-6 levels (Table 3). In each
racial/ethnic group, participants with
higher levels of IL-6 or CRP had a higher
diabetes incidence than those with the
lowest levels. Additionally, in a given
quartile of CRP, IL-6 incidence rates
tended to be higher in each nonwhite ra-
cial/ethnic group compared with white
subjects. CRP quartile was signiﬁcantly
associatedwithincidentdiabetesafterad-
justment for model 1 variables in white,
African American, and Hispanic subjects.
AdjustmentforHOMA,andsubsequently
BMI, attenuated the associations; how-
ever, CRP quartile 4 remained associated
with incident diabetes after full adjust-
ment in African American and Hispanic
participants. IL-6 was associated with in-
cident diabetes after adjustment for
model 1 variables in all groups except
Chinese. As with CRP, the magnitude of
the associations were attenuated after ad-
ditionofHOMAtothemodels;subsequent
additionofBMIsuggestedthattherewasno
longer an independent association between
IL-6 and diabetes in any group.
Similar results were obtained when
repeating analyses using log-transformed
inﬂammation levels. Speciﬁcally, the risk
Table 3—HRs for incident diabetes associated with inﬂammatory marker quartiles, stratiﬁed by race/ethnicity, in MESA 2002–2007
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend
CRP
White
Rate 5.5 10.4 10.5 18.8 0.001
Model 1 1 (referent) 1.8 (0.9–3.3) 1.8 (1.0–3.5) 3.2 (1.8–5.8) 0.01
Model 2 1 (referent) 1.4 (0.8–2.6) 1.3 (0.7–2.4) 2.0 (1.1–3.6) NS
Model 3 1 (referent) 1.3 (0.7–2.4) 1.0 (0.5–2.0) 1.5 (0.8–2.9) NS
Chinese NS
Rate 12.9 14 24.3 28.6 NS
Model 1 1 (referent) 1.0 (0.5–2.0) 1.6 (0.8–3.3) 2.0 (0.7–5.8) NS
Model 2 1 (referent) 0.8 (0.4–1.8) 1.4 (0.6–2.9) 1.0 (0.3–3.6) NS
Model 3 1 (referent) 0.7 (0.3–1.5) 1.0 (0.5–2.2) 0.9 (0.3–3.0) NS
African American
Rate 12.8 14.7 20.1 33.2 0.001
Model 1 1 (referent) 1.3 (0.6–2.5) 1.7 (0.9–3.1) 2.6 (1.5–4.7) 0.01
Model 2 1 (referent) 1.2 (0.6–2.3) 1.6 (0.8–2.9) 2.2 (1.2–4.0) 0.05
Model 3 1 (referent) 1.1 (0.6–2.2) 1.5 (0.8–2.7) 1.9 (1.0–3.5) NS
Hispanic
Rate 9.8 17.5 21.2 34.4 0.001
Model 1 1 (referent) 1.8 (0.9–4.0) 2.1 (1.0–4.5) 3.5 (1.7–7.2) 0.01
Model 2 1 (referent) 1.7 (0.8–3.7) 1.7 (0.8–3.6) 2.7 (1.3–5.5) 0.05
Model 3 1 (referent) 1.7 (0.8–3.8) 1.7 (0.8–3.5) 2.5 (1.2–5.1) NS
IL-6
White
Rate 5.1 9.1 12.2 20.5 0.001
Model 1 1 (referent) 1.7 (0.9–3.4) 2.2 (1.2–4.2) 3.6 (1.9–6.7) 0.001
Model 2 1 (referent) 1.2 (0.6–2.3) 1.4 (0.7–2.7) 1.8 (0.6–3.5) NS
Model 3 1 (referent) 1.0 (0.5–2.0) 1.1 (0.6–2.2) 1.3 (0.7–2.6) NS
Chinese
Rate 9.7 23.4 18.2 22.3 NS
Model 1 1 (referent) 2.3 (1.1–4.7) 1.6 (0.7–4.1) 2.4 (0.9–5.8) NS
Model 2 1 (referent) 2.1 (1.0–4.3) 1.0 (0.4–2.7) 1.9 (0.8–4.9) NS
Model 3 1 (referent) 1.8 (0.9–3.7) 0.8 (0.3–2.1) 1.4 (0.5–3.7) NS
African American
Rate 11.0 18.0 18.6 34.8 0.001
Model 1 1 (referent) 1.5 (0.8–3.2) 1.6 (0.8–3.1) 3.0 (1.6–5.6) 0.001
Model 2 1 (referent) 1.4 (0.7–2.7) 1.4 (0.7–2.7) 2.3 (1.2–4.4) 0.01
Model 3 1 (referent) 1.3 (0.7–2.6) 1.2 (0.6–2.4) 1.9 (1.0–3.7) NS
Hispanic
Rate 12.8 18.8 17.9 34.1 0.01
Model 1 1 (referent) 1.4 (0.7–2.9) 1.3 (0.6–2.6) 2.4 (1.2–4.6) 0.02
Model 2 1 (referent) 1.2 (0.6–2.5) 0.7 (0.4–1.5) 1.2 (0.6–2.4) NS
Model 3 1 (referent) 1.2 (0.6–2.5) 0.7 (0.3–1.4) 1.1 (0.5–2.2) NS
Data are HRs (95% CI). Rate is deﬁned as the rate per 1,000 person-years. Model 1 adjusted for age, sex, race, education, site, alcohol, smoking, exercise, systolic
blood pressure, and antihypertensive medication use. Model 2  model 1 plus HOMA-IR. Model 3  model 2 plus BMI. P value for trend across quartiles is noted.
NS, not signiﬁcant.
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transformedCRPintheentiresamplewas
1.17 (95% CI 1.06–1.29) after full adjust-
ment; for IL-6, it was 1.30 (1.09–1.55) and
ﬁbrinogen 1.10 (0.65–1.84). In stratiﬁed
analyses, inﬂammation was similarly re-
lated to diabetes incidence in each racial/
ethnic group, again, except in Chinese, in
whom generally no statistically signiﬁcant
associations were observed (data not
shown).
The composite score, constructed
from the distribution of both IL-6 and
CRP, demonstrated similar patterns as
seenabove(Table4).Intheentiresample,
the rate of diabetes increased with each
quartile (P for trend 0.001). The HRs
were attenuated after adjusting for HOMA
and BMI, but participants in quartile 4 re-
mained with a 60% higher risk of incident
diabetescomparedwiththosewiththeleast
inﬂammation. In the race-ethnicity–
stratiﬁedanalyses,similarpatternswereob-
served, although for Chinese participants,
none of the trends were signiﬁcant.
CONCLUSIONS — Our results sug-
gestthatinamultiethnicsampleofAmer-
ican adults aged 45–84 years and free of
clinical CVD at baseline, people with
higher levels of CRP, IL-6, and ﬁbrinogen
have a higher incidence of diabetes over a
2- to 5-year interval. The observed pat-
terns of association were largely consis-
tent among the four racial/ethnic groups
examined. The association between in-
ﬂammation and incident diabetes was
moreconsistentforCRPandIL-6;overall,
and in each subgroup examined, rates of
incident diabetes were two- to threefold
higher for participants with levels in the
highest quartile of this sample. The in-
creased risk associated with higher levels
of these two inﬂammatory markers was
largely explained by established diabetes
riskfactorsandinparticularBMI.Consid-
eration of both IL-6 and CRP distribution
jointly showed similar patterns of associ-
ation as with either marker alone. While
ﬁbrinogen level was also associated with
incident diabetes, after adjustment for
demographics, education, smoking, alco-
hol,exercise,hypertension,andHOMA-IR,
there was no longer a signiﬁcant associa-
tion; further adjustment for BMI resulted in
no suggestion of an independent associa-
tion.
Strengths of our analyses include uti-
lizing a multiethnic, sex-balanced, and
prospective cohort study to assess inci-
dent diabetes. MESA participants were
carefully characterized with respect to
standard diabetes risk factors, including
fasting insulin. Rather than rely on self-
reported diabetes at follow-up, MESA
measured glucose and assessed medica-
tion use at the three follow-up examina-
tions. Furthermore, all blood samples
were analyzed centrally at one laboratory.
There are several limitations to our anal-
yses,however.Bydesign,MESAexcluded
subjects with prevalent CVD, potentially
limiting the generalizability of these re-
sults. We may have included some indi-
viduals with diet-controlled diabetes in
the at-risk population, as we did not con-
sider subjects with a self-report of diabe-
teswhowerenottakingmedicineandhad
normal fasting glucose to have diabetes.
On the other hand, we used the same def-
inition at follow-up, which should be a
conservative bias (potentially underesti-
mating the true incidence rate). The fail-
Table 4—Association between a composite score composed of IL-6 and CRP and incident diabetes in MESA 2002–2007
Sample
Quartile
P trend 1 234
Overall (n  5,437)
Rate 8.6 12.1 16.7 28.5 0.001
Model 1 1 (referent) 1.5 (1.1–2.1) 1.8 (1.3–2.5) 3.0 (2.2–4.2) 0.001
Model 2 1 (referent) 1.3 (0.9–1.8) 1.4 (1.0–1.9) 2.0 (1.4–2.8) 0.001
Model 3 1 (referent) 1.2 (0.8–1.4) 1.2 (0.8–1.7) 1.6 (1.1–2.2) 0.03
White (n  2,311)
Rate 5.9 7.2 11.0 22.3
Model 1 1 (referent) 1.2 (0.6–2.4) 1.8 (1.0–3.4) 3.7 (2.0–6.6) 0.001
Model 2 1 (referent) 0.8 (0.4–1.6) 1.2 (0.6–2.2) 1.8 (1.0–3.3) 0.02
Model 3 1 (referent) 0.7 (0.4–1.4) 0.9 (0.5–1.8) 1.3 (0.7–2.5) NS
Chinese (n  633)
Rate 11.1 23.8 14.2 25.6 NS
Model 1 1 (referent) 2.1 (1.0–4.1) 1.1 (0.4–3.0) 2.2 (0.9–3.0) NS
Model 2 1 (referent) 1.6 (0.8–3.3) 0.9 (0.4–2.5) 1.4 (0.5–3.8) NS
Model 3 1 (referent) 1.4 (0.7–2.8) 0.6 (0.2–1.7) 1.1 (0.4–3.0) NS
African American (n  1,376)
Rate 9.7 13.6 23.3 33.5 0.001
Model 1 1 (referent) 1.5 (0.7–3.1) 2.4 (1.2–4.8) 3.5 (1.8–6.8) 0.001
Model 2 1 (referent) 1.4 (0.7–3.0) 2.1 (1.1–4.2) 2.7 (1.4–5.3) 0.01
Model 3 1 (referent) 1.3 (0.6–2.8) 1.9 (1.0–3.9) 2.2 (1.1–4.5) NS
Hispanic (n  1,117)
Rate 12.0 18.6 19.8 32.7 0.01
Model 1 1 (referent) 1.5 (0.7–3.0) 1.5 (0.7–3.1) 2.5 (1.3–4.9) 0.03
Model 2 1 (referent) 1.1 (0.5–2.2) 0.9 (0.4–1.9) 1.4 (0.7–2.9) NS
Model 3 1 (referent) 1.0 (0.5–2.2) 0.9 (0.4–1.8) 1.3 (0.6–2.6) NS
Data are HRs (95% CI). Rate is deﬁned as incidence rate per 1,000 person-years. Model 1 adjusted for age, sex, race, education, site, alcohol, smoking, exercise,
systolic blood pressure, and antihypertensive medication use. Model 2  model 1 plus HOMA-IR. Model 3  model 2 plus BMI. P value for trend across quartiles
is noted. NS, not signiﬁcant.
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ethnicity may reﬂect inadequate power.
We did not have adequate sample size to
present analyses stratiﬁed by race/
ethnicity and sex. Biomarkers were only
measured once, and intraindividual vari-
abilitycannotbeaccountedfor.However,
assay variability would be expected to
bias ﬁndings toward the null so the ob-
served associations are potentially under-
estimations.
Our ﬁndings among Chinese partici-
pants merit some discussion. The appar-
ently different relationships between
inﬂammation and incident diabetes may
be solely due to insufﬁcient power rather
than any biological differences. Of note,
wefoundfewstudiesassessinginﬂamma-
tion level and diabetes in Chinese sub-
jects,althoughCRPdidappearassociated
with type 2 diabetes in a cross-sectional
study (17). CRP was associated with re-
mainingglucoseintolerantorprogressing
to diabetes among 228 Hong Kong Chi-
nese with impaired glucose tolerance;
however, only 21 participants developed
diabetes, precluding analyses about inci-
dent diabetes (18). The lower levels of in-
ﬂammation present among Chinese in
thissamplemayalsoexplainourﬁndings,
if there is a threshold effect. At least one
study (19) including U.S. resident Chi-
nese women also reported lower levels of
CRP compared with other race/ethnic
participants, even after adjusting for BMI
differences.
The current epidemic of diabetes is
projectedtoworsensuchthatupto7%of
the U.S. population will be affected by
2050(from4%in2000);upto37%ofthe
increased prevalence is estimated to be
due to projected changes in the country’s
demographic composition with a de-
crease in whites and increase in minority
groups (20). As such, investigating diabe-
tes incidence in a multiethnic sample is
important. One recent analysis (21) in a
multiethnic cohort of postmenopausal
womensuggestedbothCRPandIL-6pre-
dicted incident diabetes similarly in
white, black, Hispanic, and Asian/Paciﬁc
Islander subjects. There are several im-
portant differences between the study by
Liu et al. (21) and the present one herein,
including a case-control design and reli-
ance on self-report or hospital discharge
diagnoses; nevertheless, they also ob-
served signiﬁcant attenuation of the asso-
ciation between CRP or IL-6 and incident
diabetes when adjusting for BMI and
baseline fasting glucose. CRP remained
associated with incident diabetes in the
Insulin Resistance and Atherosclerosis
Study (a white, African American, and
Hispanic cohort) after adjustment for
metabolicsyndromevariablesandinsulin
resistance; however, they did not present
astratiﬁedanalysis(22).Wearenotaware
ofotherstudiesreportingstratiﬁedresults
from a multiethnic sample including
men.Ourresultssuggestthattherelation-
ship between both CRP and IL-6 and in-
cident diabetes is likely to be largely
mediated by insulin resistance and adi-
posity in these racial/ethnic groups. Fat
cells, in particular visceral adipocytes, are
known to be important producers of in-
ﬂammatory proteins. There is substantial
debate whether inﬂammation is directly
playing a pathophysiologic role or
whether it is simply a marker for under-
lying processes that affect both insulin
sensitivity and inﬂammation levels (10).
Our results suggest that CRP and
IL-6, or a composite score encompassing
both, but not ﬁbrinogen level, may be
considered as potentially independent
predictors of diabetes in a racially diverse
population such as the U.S. It is plausible
that inﬂammatory markers may be uti-
lizedtoreﬁnediabetesriskpredictionand
thus better target (or motivate) individu-
als for lifestyle interventions. However,
we note that CRP levels did not apprecia-
bly improve diabetes risk prediction in
the Framingham Offspring cohort or the
Insulin Resistance and Atherosclerosis
Study (22,23). One potential implication
of the many studies demonstrating a rela-
tionship between inﬂammation and dia-
betes is that trials of anti-inﬂammatory
agentsbeundertakentopreventdiabetes.
However, a recent randomized trial failed
to demonstrate that chronic aspirin use
prevented incident diabetes in women
(24). In contrast, the Finish Diabetes Pre-
vention Study lifestyle intervention re-
ducedCRPandIL-6(25).Futureresearch
aimed at understanding the potential
causalrelationshipbetweeninﬂammation
and diabetes may yield novel approaches
to preventing diabetes. However, it re-
mains important to focus on ways to in-
creaseadherencetolifestyleinterventions
of exercise and diet to reduce diabetes
risk.
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